This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Halozyme Therapeutics has stopped its pivotal phase 3 study investigating its lead pancreatic cancer drug – and has announced a major restructuring of its workforce that has resulted in a 55% reduction ... In 2015, AbbVie paid Halozyme nearly $1.2bn
FDA says PEGPH20 trial can continue. There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to
The biopharma company is investigating PEGPH20’s links to blood clot. Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the ... As for the fate of PEGPH20, Halozyme's CEO Dr Helen Torley
HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Halozyme receives $9m upfront and up to $54m in development and regulatory milestones. ... Commercialisation. 134. Halozyme Therapeutics/Intrexon Corp. rHuPH20 enzyme drug delivery. technology for COPD and genetic emphysema.
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...